Selected research
Industry Research
Nocturia Industry Research Report 2026
Market perspective
The global Nocturia market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Nocturia market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Nocturia market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Nocturia market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Nocturia include Abbott, Allergan, APOTEX INC, Astellas Pharma, Astra Zeneca, Bristol-Myers Squibb, Eli Lilly, Ferring Pharmaceuticals and GlaxoSmithKline, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Nocturia market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Nocturia.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Nocturia Market by Company
Abbott
Allergan
APOTEX INC
Astellas Pharma
Astra Zeneca
Bristol-Myers Squibb
Eli Lilly
Ferring Pharmaceuticals
GlaxoSmithKline
Johnson & Johnson
Merck
Mylan
Novartis
Pfizer
Rechon Life Science AB
Sagent Pharmaceuticals
Sanofi
Sun Pharmaceutical Industries Ltd.
Teva
Chengdu Leer Pharmaceutical
Fosun Pharma
Hainan Zhonghe Pharmaceutical
Nanjing Xingyin Pharmaceutical Group
Hybio Pharmaceutical
Zhejiang Conba Pharmaceutical
Nocturia Segment by Type
Desmopressin
Diuretics
Anticholinergic Drugs
Alpha Blockers
Others
Nocturia Segment by Application
Retail Pharmacies
Online Pharmacies
Hospital Pharmacies
Nocturia Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nocturia market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nocturia and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nocturia.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Nocturia companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Desmopressin
- Diuretics
- Anticholinergic Drugs
- Alpha Blockers
- Others
Applications
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
Companies covered
- Abbott
- Allergan
- APOTEX INC
- Astellas Pharma
- Astra Zeneca
- Bristol-Myers Squibb
- Eli Lilly
- Ferring Pharmaceuticals
- GlaxoSmithKline
- Johnson & Johnson
- Merck
- Mylan
- Novartis
- Pfizer
- Rechon Life Science AB
- Sagent Pharmaceuticals
- Sanofi
- Sun Pharmaceutical Industries Ltd.
- Teva
- Chengdu Leer Pharmaceutical
- Fosun Pharma
- Hainan Zhonghe Pharmaceutical
- Nanjing Xingyin Pharmaceutical Group
- Hybio Pharmaceutical
- Zhejiang Conba Pharmaceutical
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Nocturia by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Desmopressin
- 2.2.3 Diuretics
- 2.2.4 Anticholinergic Drugs
- 2.2.5 Alpha Blockers
- 2.2.6 Others
- 2.3 Nocturia by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Retail Pharmacies
- 2.3.3 Online Pharmacies
- 2.3.4 Hospital Pharmacies
- 2.4 Assumptions and Limitations
3 Nocturia Breakdown Data by Type
- 3.1 Global Nocturia Historic Market Size by Type (2021-2026)
- 3.2 Global Nocturia Forecasted Market Size by Type (2027-2032)
4 Nocturia Breakdown Data by Application
- 4.1 Global Nocturia Historic Market Size by Application (2021-2026)
- 4.2 Global Nocturia Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Nocturia Market Perspective (2021-2032)
- 5.2 Global Nocturia Growth Trends by Region
- 5.2.1 Global Nocturia Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Nocturia Historic Market Size by Region (2021-2026)
- 5.2.3 Nocturia Forecasted Market Size by Region (2027-2032)
- 5.3 Nocturia Market Dynamics
- 5.3.1 Nocturia Industry Trends
- 5.3.2 Nocturia Market Drivers
- 5.3.3 Nocturia Market Challenges
- 5.3.4 Nocturia Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Nocturia Players by Revenue
- 6.1.1 Global Top Nocturia Players by Revenue (2021-2026)
- 6.1.2 Global Nocturia Revenue Market Share by Players (2021-2026)
- 6.2 Global Nocturia Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Nocturia Head Office and Area Served
- 6.4 Global Nocturia Players, Product Type & Application
- 6.5 Global Nocturia Manufacturers Established Date
- 6.6 Global Nocturia Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Nocturia Market Size (2021-2032)
- 7.2 North America Nocturia Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Nocturia Market Size by Country (2021-2026)
- 7.4 North America Nocturia Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Nocturia Market Size (2021-2032)
- 8.2 Europe Nocturia Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Nocturia Market Size by Country (2021-2026)
- 8.4 Europe Nocturia Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Nocturia Market Size (2021-2032)
- 9.2 Asia-Pacific Nocturia Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Nocturia Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Nocturia Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Nocturia Market Size (2021-2032)
- 10.2 South America Nocturia Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Nocturia Market Size by Country (2021-2026)
- 10.4 South America Nocturia Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Nocturia Market Size (2021-2032)
- 11.2 Middle East & Africa Nocturia Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Nocturia Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Nocturia Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Abbott
- 12.1.1 Abbott Company Information
- 12.1.2 Abbott Business Overview
- 12.1.3 Abbott Revenue in Nocturia Business (2021-2026)
- 12.1.4 Abbott Nocturia Product Portfolio
- 12.1.5 Abbott Recent Developments
- 12.2 Allergan
- 12.2.1 Allergan Company Information
- 12.2.2 Allergan Business Overview
- 12.2.3 Allergan Revenue in Nocturia Business (2021-2026)
- 12.2.4 Allergan Nocturia Product Portfolio
- 12.2.5 Allergan Recent Developments
- 12.3 APOTEX INC
- 12.3.1 APOTEX INC Company Information
- 12.3.2 APOTEX INC Business Overview
- 12.3.3 APOTEX INC Revenue in Nocturia Business (2021-2026)
- 12.3.4 APOTEX INC Nocturia Product Portfolio
- 12.3.5 APOTEX INC Recent Developments
- 12.4 Astellas Pharma
- 12.4.1 Astellas Pharma Company Information
- 12.4.2 Astellas Pharma Business Overview
- 12.4.3 Astellas Pharma Revenue in Nocturia Business (2021-2026)
- 12.4.4 Astellas Pharma Nocturia Product Portfolio
- 12.4.5 Astellas Pharma Recent Developments
- 12.5 Astra Zeneca
- 12.5.1 Astra Zeneca Company Information
- 12.5.2 Astra Zeneca Business Overview
- 12.5.3 Astra Zeneca Revenue in Nocturia Business (2021-2026)
- 12.5.4 Astra Zeneca Nocturia Product Portfolio
- 12.5.5 Astra Zeneca Recent Developments
- 12.6 Bristol-Myers Squibb
- 12.6.1 Bristol-Myers Squibb Company Information
- 12.6.2 Bristol-Myers Squibb Business Overview
- 12.6.3 Bristol-Myers Squibb Revenue in Nocturia Business (2021-2026)
- 12.6.4 Bristol-Myers Squibb Nocturia Product Portfolio
- 12.6.5 Bristol-Myers Squibb Recent Developments
- 12.7 Eli Lilly
- 12.7.1 Eli Lilly Company Information
- 12.7.2 Eli Lilly Business Overview
- 12.7.3 Eli Lilly Revenue in Nocturia Business (2021-2026)
- 12.7.4 Eli Lilly Nocturia Product Portfolio
- 12.7.5 Eli Lilly Recent Developments
- 12.8 Ferring Pharmaceuticals
- 12.8.1 Ferring Pharmaceuticals Company Information
- 12.8.2 Ferring Pharmaceuticals Business Overview
- 12.8.3 Ferring Pharmaceuticals Revenue in Nocturia Business (2021-2026)
- 12.8.4 Ferring Pharmaceuticals Nocturia Product Portfolio
- 12.8.5 Ferring Pharmaceuticals Recent Developments
- 12.9 GlaxoSmithKline
- 12.9.1 GlaxoSmithKline Company Information
- 12.9.2 GlaxoSmithKline Business Overview
- 12.9.3 GlaxoSmithKline Revenue in Nocturia Business (2021-2026)
- 12.9.4 GlaxoSmithKline Nocturia Product Portfolio
- 12.9.5 GlaxoSmithKline Recent Developments
- 12.10 Johnson & Johnson
- 12.10.1 Johnson & Johnson Company Information
- 12.10.2 Johnson & Johnson Business Overview
- 12.10.3 Johnson & Johnson Revenue in Nocturia Business (2021-2026)
- 12.10.4 Johnson & Johnson Nocturia Product Portfolio
- 12.10.5 Johnson & Johnson Recent Developments
- 12.11 Merck
- 12.11.1 Merck Company Information
- 12.11.2 Merck Business Overview
- 12.11.3 Merck Revenue in Nocturia Business (2021-2026)
- 12.11.4 Merck Nocturia Product Portfolio
- 12.11.5 Merck Recent Developments
- 12.12 Mylan
- 12.12.1 Mylan Company Information
- 12.12.2 Mylan Business Overview
- 12.12.3 Mylan Revenue in Nocturia Business (2021-2026)
- 12.12.4 Mylan Nocturia Product Portfolio
- 12.12.5 Mylan Recent Developments
- 12.13 Novartis
- 12.13.1 Novartis Company Information
- 12.13.2 Novartis Business Overview
- 12.13.3 Novartis Revenue in Nocturia Business (2021-2026)
- 12.13.4 Novartis Nocturia Product Portfolio
- 12.13.5 Novartis Recent Developments
- 12.14 Pfizer
- 12.14.1 Pfizer Company Information
- 12.14.2 Pfizer Business Overview
- 12.14.3 Pfizer Revenue in Nocturia Business (2021-2026)
- 12.14.4 Pfizer Nocturia Product Portfolio
- 12.14.5 Pfizer Recent Developments
- 12.15 Rechon Life Science AB
- 12.15.1 Rechon Life Science AB Company Information
- 12.15.2 Rechon Life Science AB Business Overview
- 12.15.3 Rechon Life Science AB Revenue in Nocturia Business (2021-2026)
- 12.15.4 Rechon Life Science AB Nocturia Product Portfolio
- 12.15.5 Rechon Life Science AB Recent Developments
- 12.16 Sagent Pharmaceuticals
- 12.16.1 Sagent Pharmaceuticals Company Information
- 12.16.2 Sagent Pharmaceuticals Business Overview
- 12.16.3 Sagent Pharmaceuticals Revenue in Nocturia Business (2021-2026)
- 12.16.4 Sagent Pharmaceuticals Nocturia Product Portfolio
- 12.16.5 Sagent Pharmaceuticals Recent Developments
- 12.17 Sanofi
- 12.17.1 Sanofi Company Information
- 12.17.2 Sanofi Business Overview
- 12.17.3 Sanofi Revenue in Nocturia Business (2021-2026)
- 12.17.4 Sanofi Nocturia Product Portfolio
- 12.17.5 Sanofi Recent Developments
- 12.18 Sun Pharmaceutical Industries Ltd.
- 12.18.1 Sun Pharmaceutical Industries Ltd. Company Information
- 12.18.2 Sun Pharmaceutical Industries Ltd. Business Overview
- 12.18.3 Sun Pharmaceutical Industries Ltd. Revenue in Nocturia Business (2021-2026)
- 12.18.4 Sun Pharmaceutical Industries Ltd. Nocturia Product Portfolio
- 12.18.5 Sun Pharmaceutical Industries Ltd. Recent Developments
- 12.19 Teva
- 12.19.1 Teva Company Information
- 12.19.2 Teva Business Overview
- 12.19.3 Teva Revenue in Nocturia Business (2021-2026)
- 12.19.4 Teva Nocturia Product Portfolio
- 12.19.5 Teva Recent Developments
- 12.20 Chengdu Leer Pharmaceutical
- 12.20.1 Chengdu Leer Pharmaceutical Company Information
- 12.20.2 Chengdu Leer Pharmaceutical Business Overview
- 12.20.3 Chengdu Leer Pharmaceutical Revenue in Nocturia Business (2021-2026)
- 12.20.4 Chengdu Leer Pharmaceutical Nocturia Product Portfolio
- 12.20.5 Chengdu Leer Pharmaceutical Recent Developments
- 12.21 Fosun Pharma
- 12.21.1 Fosun Pharma Company Information
- 12.21.2 Fosun Pharma Business Overview
- 12.21.3 Fosun Pharma Revenue in Nocturia Business (2021-2026)
- 12.21.4 Fosun Pharma Nocturia Product Portfolio
- 12.21.5 Fosun Pharma Recent Developments
- 12.22 Hainan Zhonghe Pharmaceutical
- 12.22.1 Hainan Zhonghe Pharmaceutical Company Information
- 12.22.2 Hainan Zhonghe Pharmaceutical Business Overview
- 12.22.3 Hainan Zhonghe Pharmaceutical Revenue in Nocturia Business (2021-2026)
- 12.22.4 Hainan Zhonghe Pharmaceutical Nocturia Product Portfolio
- 12.22.5 Hainan Zhonghe Pharmaceutical Recent Developments
- 12.23 Nanjing Xingyin Pharmaceutical Group
- 12.23.1 Nanjing Xingyin Pharmaceutical Group Company Information
- 12.23.2 Nanjing Xingyin Pharmaceutical Group Business Overview
- 12.23.3 Nanjing Xingyin Pharmaceutical Group Revenue in Nocturia Business (2021-2026)
- 12.23.4 Nanjing Xingyin Pharmaceutical Group Nocturia Product Portfolio
- 12.23.5 Nanjing Xingyin Pharmaceutical Group Recent Developments
- 12.24 Hybio Pharmaceutical
- 12.24.1 Hybio Pharmaceutical Company Information
- 12.24.2 Hybio Pharmaceutical Business Overview
- 12.24.3 Hybio Pharmaceutical Revenue in Nocturia Business (2021-2026)
- 12.24.4 Hybio Pharmaceutical Nocturia Product Portfolio
- 12.24.5 Hybio Pharmaceutical Recent Developments
- 12.25 Zhejiang Conba Pharmaceutical
- 12.25.1 Zhejiang Conba Pharmaceutical Company Information
- 12.25.2 Zhejiang Conba Pharmaceutical Business Overview
- 12.25.3 Zhejiang Conba Pharmaceutical Revenue in Nocturia Business (2021-2026)
- 12.25.4 Zhejiang Conba Pharmaceutical Nocturia Product Portfolio
- 12.25.5 Zhejiang Conba Pharmaceutical Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst